Dendritic Cell Immunotherapy for Glioblastoma
Trial Summary
What is the purpose of this trial?
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Researchers will compare DOC1021 dendritic cell immunotherapy regimen added to SOC compared to SOC treatment alone. Participants in the DOC1021 + pIFN + SOC arm will: * Take filgrastim subcutaneously x 5 doses and subsequently undergo a leukapheresis collection * Undergo ultrasound guided perinodal DOC1021 injections every 2 weeks for a total of 3 doses * Receive subcutaneous pIFN injections weekly for a total of 6 doses in parallel with the DOC1021 injections Both arms of the trial will: - Visit the clinic regularly to assess quality of life, symptoms, medication use, imaging, bloodwork, and to receive SOC treatment with surgery, temozolomide chemotherapy and radiation
Eligibility Criteria
Adults diagnosed with a specific brain cancer called glioblastoma (IDH-wt) who haven't had other cancer treatments and are good candidates for surgery, chemotherapy, and radiation. They must be willing to follow the study plan and be available throughout the trial. Women of childbearing age need a negative pregnancy test and must use contraception.Inclusion Criteria
Treatment Details
Interventions
- DOC1021 (Cancer Vaccine)